Moleculin Biotech (MBRX) Invested Capital (2016 - 2025)
Moleculin Biotech (MBRX) has 10 years of Invested Capital data on record, last reported at -$26.9 million in Q3 2025.
- For Q3 2025, Invested Capital fell 254.61% year-over-year to -$26.9 million; the TTM value through Sep 2025 reached -$26.9 million, down 254.61%, while the annual FY2024 figure was $11.2 million, 63.76% down from the prior year.
- Invested Capital reached -$26.9 million in Q3 2025 per MBRX's latest filing, down from -$3.6 million in the prior quarter.
- Across five years, Invested Capital topped out at $88.6 million in Q1 2021 and bottomed at -$26.9 million in Q3 2025.
- Average Invested Capital over 5 years is $41.7 million, with a median of $40.3 million recorded in 2023.
- Peak YoY movement for Invested Capital: surged 479.46% in 2021, then plummeted 254.61% in 2025.
- A 5-year view of Invested Capital shows it stood at $79.1 million in 2021, then crashed by 33.91% to $52.3 million in 2022, then crashed by 40.84% to $30.9 million in 2023, then tumbled by 63.76% to $11.2 million in 2024, then tumbled by 340.19% to -$26.9 million in 2025.
- Per Business Quant database, its latest 3 readings for Invested Capital were -$26.9 million in Q3 2025, -$3.6 million in Q2 2025, and $13.8 million in Q1 2025.